Generic name: TENOFOVIR ALAFENAMIDE FUMARATE 25mg
Dosage form: tablet
Medically reviewed on July 9, 2018.
Testing Prior to Initiation of VEMLIDY
Prior to initiation of VEMLIDY, patients should be tested for HIV-1 infection. VEMLIDY alone should not be used in patients with HIV-1 infection [see Warnings and Precautions (5.2)].
Prior to or when initiating VEMLIDY, and during treatment with VEMLIDY on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions (5.3)].
Recommended Dosage in Adults
The recommended dosage of VEMLIDY is 25 mg (one tablet) taken orally once daily with food [see Clinical Pharmacology (12.3)].
Dosage in Patients with Renal Impairment
No dosage adjustment of VEMLIDY is required in patients with mild, moderate, or severe renal impairment. VEMLIDY is not recommended in patients with end stage renal disease (estimated creatinine clearance below 15 mL per minute) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
Dosage in Patients with Hepatic Impairment
No dosage adjustment of VEMLIDY is required in patients with mild hepatic impairment (Child-Pugh A). VEMLIDY is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Vemlidy (tenofovir alafenamide)
- Vemlidy Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Pricing & Coupons
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)